Cookie Policy

We have placed cookies on your device for this site to work correctly and to help improve the user experience. If you click on 'OK' we will continue to store cookies on your device enabling you to benefit from the site's full functionality. You can change your cookie settings at any time using your browser. For more information on this and our cookie policy please refer to the cookie section in our Legal Statement.



When defensives aren't defensive

August 2017
3 mins. To Read

Buy low, sell high—a sure way to make money. But today, stockmarket valuations look high in several regions. On a price-to-earnings basis, the US market has been this expensive only 12% of the time over the past 40 years, for example. If we aim to buy low and sell high, what can we do in this environment?

As always, we focus on finding undervalued individual securities. In mature bull markets, there are often good opportunities among “defensive” shares—businesses with steady growth, stable profits, and solid balance sheets. Through booms and busts, people still buy food, medicine, and electricity, so companies in the consumer staples, health care, and utility sectors tend to be less cyclical. When these defensive businesses are available at reasonable valuations, they have historically offered good protection against wider market declines.

We have seen this three times in our history. In the run-up to the Japan bubble in 1990, the tech bubble in 2000, and the global financial crisis in 2008, boring defensives became attractively priced as excited investors flocked to more exciting shares. When the bubbles burst, defensives held up well, as investors rediscovered their appreciation of reliable fundamentals.

The situation today looks different. Markets are expensive, but so are defensives. Investors haven’t lost their appreciation of reliable fundamentals—if anything, they look to be placing too much value on predictability.

One reason is the unprecedented quantitative easing (QE) from central banks globally since the financial crisis. As central banks buy up bonds, their yields decline, forcing investors to go elsewhere for returns. Many investors have turned to equities, and in particular to defensive shares with bond-like characteristics.

This is borne out in the data. From 1990 to the beginning of the “QE era” in December 2008, there was little correlation between bond yields and the valuations of defensive shares versus the wider market. Since 2008, however, the link has been ironclad: when bond yields fall, defensives get more expensive, and when bond yields rise, defensives get cheaper.

Though global bond yields have bounced from the levels of mid-2016, they remain near record lows, leaving bond-like equities potentially vulnerable. With rich valuations and unfavourable exposure to higher interest rates, defensives look anything but.

There are exceptions. As Betsy Lind discussed in May, we have found attractive opportunities in healthcare stocks such as AbbVie. We believe these shares will ultimately provide ample compensation for accepting a little bit of uncertainty. And in more cyclical areas, we believe uncertainty has left a larger number of shares trading at attractive prices given their long-term prospects. For XPO Logistics, investors fret about the company’s acquisition strategy. For Chinese e-commerce firm, uncertainty comes from competition with Alibaba. For radio systems leader Motorola Solutions, the uncertainty is around the company’s growth potential in public safety systems. In each case, we see quality businesses with a high chance of delivering good fundamental results. The range of fundamental outcomes for each company may be wider than for a Unilever or a Johnson & Johnson, but so long as that range of outcomes is favourable, we are happy to be roughly right. Accepting some uncertainty lets us seek protection against losses in the best way we know—buying assets for less than we think they are worth.

This Report does not constitute advice nor a recommendation to buy, sell or hold, nor an offer to sell or a solicitation to buy interests or shares in the Orbis Funds or other securities in the companies mentioned in it (“relevant securities”). It has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Orbis, its affiliates, directors and employees (together, the “Orbis Group”) are not subject to restrictions on dealing in relevant securities ahead of the dissemination of this Report. Subscriptions are only valid if made on the basis of the current Prospectus of an Orbis Fund.

 Notice - this site is optimised for desktop use.

Thank you for visiting the Orbis website. Please note that some functionality on tablets and smartphones may be limited as the site was developed for desktop use.